Department of Haematology, Manchester University Hospitals, Manchester, UK.
Laboratory of Experimental Intensive Care and Anesthesiology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
J Thromb Haemost. 2020 Sep;18(9):2138-2144. doi: 10.1111/jth.15004.
Hypercoagulability is an increasingly recognized complication of SARS-CoV-2 infection. As such, anticoagulation has become part and parcel of comprehensive COVID-19 management. However, several uncertainties exist in this area, including the appropriate type and dose of heparin. In addition, special patient populations, including those with high body mass index and renal impairment, require special consideration. Although the current evidence is still insufficient, we provide a pragmatic approach to anticoagulation in COVID-19, but stress the need for further trials in this area.
高凝状态是 SARS-CoV-2 感染的一种日益被认识到的并发症。因此，抗凝已成为 COVID-19 综合管理不可或缺的一部分。然而，该领域存在一些不确定性，包括肝素的适当类型和剂量。此外，包括高体重指数和肾功能损害在内的特殊患者群体需要特别考虑。尽管目前的证据仍然不足，但我们提供了一种针对 COVID-19 的抗凝实用方法，但强调需要在这一领域进行进一步的试验。
